Astrazeneca Plc Adr Stock Price To Earning
| AZN Stock | USD 75.17 0.14 0.19% |
AstraZeneca PLC ADR fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca | Price To Earning |
AstraZeneca PLC ADR Company Price To Earning Analysis
AstraZeneca PLC's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current AstraZeneca PLC Price To Earning | 103.39 X |
Most of AstraZeneca PLC's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AstraZeneca Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for AstraZeneca PLC is extremely important. It helps to project a fair market value of AstraZeneca Stock properly, considering its historical fundamentals such as Price To Earning. Since AstraZeneca PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AstraZeneca PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AstraZeneca PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
AstraZeneca Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, AstraZeneca PLC ADR has a Price To Earning of 103 times. This is 300.12% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is notably lower than that of the firm.
AstraZeneca Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in price to earning category among related companies.
AstraZeneca Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0704 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 143.17 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.83 % | ||||
| Number Of Shares Shorted | 8.58 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 45.81 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 13.91 B | ||||
| Net Income | 6.9 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 28.62 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 24.17 X | ||||
| Cash Flow From Operations | 10.35 B | ||||
| Short Ratio | 1.61 X | ||||
| Earnings Per Share | 2.02 X | ||||
| Price To Earnings To Growth | 0.89 X | ||||
| Target Price | 81.72 | ||||
| Number Of Employees | 89.9 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 233.06 B | ||||
| Total Asset | 101.12 B | ||||
| Retained Earnings | 1.5 B | ||||
| Working Capital | (5.49 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 2.99 % | ||||
| Net Asset | 101.12 B | ||||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Stock
| 0.81 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.72 | CRBU | Caribou Biosciences Financial Report 14th of May 2024 | PairCorr |
| 0.6 | MOLN | Molecular Partners Financial Report 10th of May 2024 | PairCorr |
| 0.57 | NAUT | Nautilus Biotechnology Financial Report 7th of May 2024 | PairCorr |
| 0.54 | IPSC | Century Therapeutics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AstraZeneca PLC Piotroski F Score and AstraZeneca PLC Altman Z Score analysis. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.207 | Dividend Share 2.9 | Earnings Share 2.02 | Revenue Per Share 2.5512 | Quarterly Revenue Growth 0.165 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.